Induction of Heme Oxygenase-1 Can Halt and Even Reverse Renal Tubule-interstitial Fibrosis
Overview
Authors
Affiliations
Background: The tubule-interstitial fibrosis is the hallmark of progressive renal disease and is strongly associated with inflammation of this compartment. Heme-oxygenase-1 (HO-1) is a cytoprotective molecule that has been shown to be beneficial in various models of renal injury. However, the role of HO-1 in reversing an established renal scar has not yet been addressed.
Aim: We explored the ability of HO-1 to halt and reverse the establishment of fibrosis in an experimental model of chronic renal disease.
Methods: Sprague-Dawley male rats were subjected to unilateral ureteral obstruction (UUO) and divided into two groups: non-treated and Hemin-treated. To study the prevention of fibrosis, animals were pre-treated with Hemin at days -2 and -1 prior to UUO. To investigate whether HO-1 could reverse established fibrosis, Hemin therapy was given at days 6 and 7 post-surgery. After 7 and/or 14 days, animals were sacrificed and blood, urine and kidney tissue samples were collected for analyses. Renal function was determined by assessing the serum creatinine, inulin clearance, proteinuria/creatininuria ratio and extent of albuminuria. Arterial blood pressure was measured and fibrosis was quantified by Picrosirius staining. Gene and protein expression of pro-inflammatory and pro-fibrotic molecules, as well as HO-1 were performed.
Results: Pre-treatment with Hemin upregulated HO-1 expression and significantly reduced proteinuria, albuminuria, inflammation and pro-fibrotic protein and gene expressions in animals subjected to UUO. Interestingly, the delayed treatment with Hemin was also able to reduce renal dysfunction and to decrease the expression of pro-inflammatory molecules, all in association with significantly reduced levels of fibrosis-related molecules and collagen deposition. Finally, TGF-β protein production was significantly lower in Hemin-treated animals.
Conclusion: Treatment with Hemin was able both to prevent the progression of fibrosis and to reverse an established renal scar. Modulation of inflammation appears to be the major mechanism behind HO-1 cytoprotection.
Castro B, Reno P, Pereira B, Arriel K, Bonato F, Colugnati F J Bras Nefrol. 2024; 46(4):e20230148.
PMID: 39412511 PMC: 11539900. DOI: 10.1590/2175-8239-JBN-2023-0148en.
The roles of heme oxygenase-1 in renal disease.
Zhai H, Ni L, Wu X Front Nephrol. 2023; 3:1156346.
PMID: 37675385 PMC: 10479750. DOI: 10.3389/fneph.2023.1156346.
The long-term renal effects of short periods of unilateral ureteral obstruction.
Hammad F Int J Physiol Pathophysiol Pharmacol. 2022; 14(2):60-72.
PMID: 35619661 PMC: 9123473.
Zhang X, Li X Metabolites. 2022; 12(1).
PMID: 35050181 PMC: 8779729. DOI: 10.3390/metabo12010058.
Immunomodulatory Effects of Heme Oxygenase-1 in Kidney Disease.
Li Y, Ma K, Han Z, Chi M, Sai X, Zhu P Front Med (Lausanne). 2021; 8:708453.
PMID: 34504854 PMC: 8421649. DOI: 10.3389/fmed.2021.708453.